phrykt

Cue Biopharma, Inc. (CUE): who owns it and who trades it

As of Nov 16, 2026, CUE insiders reported 15 open-market sales worth $2.4M and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Shao-Lee Lin (CEO), with $1.9M. 3 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Cue Biopharma

From the latest filings

Overall: more selling than buying. Insiders and famous investors mostly sold.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns CUE

48 funds and institutions reported CUE shares worth $51.8M at the end of Q2 2026, about 2% of the company. The largest holder is Bleichroeder LP with 0.4%.

Funds and institutions (13F) 2%Everyone else 98%

10 largest owners, by share of the company

Bleichroeder LP0.4%
Driehaus Capital Management LLC0.3%
Vanguard Capital Management LLC0.2%
Ikarian Capital, LLC0.1%
Tetragon Partners GP Ltd0.1%
Stempoint Capital LP0.1%
BlackRock, Inc.0.1%
ADAR1 Capital Management, LLC0.1%
Lion Point Capital, LP0.1%
Squadron Capital Management LLC0.1%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Bleichroeder LP370,6820.38%$11.7M–
Driehaus Capital Management LLC292,1440.30%$9.2M–
Vanguard Capital Management LLC161,7000.17%$5.1M–
Ikarian Capital, LLC104,3640.11%$3.3M–
Tetragon Partners GP Ltd93,8190.10%$3M–
Stempoint Capital LP66,9950.07%$2.1M–
BlackRock, Inc.57,8070.06%$1.8M–
ADAR1 Capital Management, LLC55,1930.06%$1.7M–
Lion Point Capital, LP52,9280.05%$1.7M–
Squadron Capital Management LLC50,0000.05%$1.6M–
Diadema Partners LP48,3690.05%$1.5M–
Geode Capital Management, LLC47,8240.05%$1.5M–
Boothbay Fund Management, LLC31,4590.03%$993K–
UBS Group AG26,7000.03%$843K–
Citadel Advisors LLC25,6330.03%$809K–
Vanguard Fiduciary Trust Co24,4760.03%$772K–
Texas Capital Bank Wealth Management Services Inc22,8810.02%$722K–
Renaissance Technologies LLC14,6890.02%$464K–
Persistent Asset Partners Ltd12,3320.01%$389K–
Robertson Stephens Wealth Management, LLC11,1330.01%$351K–

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, CUE insiders reported $0 of open-market purchases and $2.4M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$2.4M
15 trades, 3 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Oct 12, 2026
Filed Oct 14, 2026

Purchases and sales by month

$2M$2MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Oct 12, 2026Sumita RayChief Legal Compliance OSale1,844$28.05$51.7KForm 4
Oct 12, 2026Shao-Lee LinCEOSale10,000$27.50$275KForm 4
Oct 12, 2026Shao-Lee LinCEOSale1,087$28.05$30.5KForm 4
Oct 12, 2026Michael Vincent MeluzioVice presidentSale1,144$28.05$32.1KForm 4
Aug 13, 2026Sumita RayChief Legal Compliance OSale2,383$29.37$70KForm 4
Aug 13, 2026Sumita RayChief Legal Compliance OSale6,442$30.35$196KForm 4
Aug 13, 2026Sumita RayChief Legal Compliance OSale4$31.13$125Form 4
Aug 13, 2026Michael Vincent MeluzioVice presidentSale3$31.13$93Form 4
Aug 13, 2026Michael Vincent MeluzioVice presidentSale4,106$30.35$125KForm 4
Aug 13, 2026Michael Vincent MeluzioVice presidentSale1,519$29.37$44.6KForm 4
Aug 13, 2026Shao-Lee LinCEOSale5,423$27.19$147KForm 4
Aug 13, 2026Shao-Lee LinCEOSale10,460$29.48$308KForm 4
Aug 13, 2026Shao-Lee LinCEOSale2,375$28.11$66.8KForm 4
Aug 12, 2026Shao-Lee LinCEOSale34,225$26.99$924KForm 4
Aug 12, 2026Shao-Lee LinCEOSale5,775$27.75$160KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Shao-Lee LinChief Executive Officer, Director–$1.9MOct 12, 2026
Sumita RayChief Legal Compliance Officer–$317KOct 12, 2026
Michael Vincent MeluzioVP, Prin. Accounting Officer–$201KOct 12, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

CUE short interest

High short interest. 11.9% of CUE shares are sold short: about 1 share in 8. Over the last 12 reports the number of shares short went up 238%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 862,798 CUE shares were sold short, 11.9% of the shares outstanding, up 8.9% from the report before. At the average daily volume of 113,963 shares, buying them all back would take about 7.6 trading days (days to cover).

Shares short, % of all shares

11.9%May 15Oct 3013.6%

Days to cover

7.6May 15Oct 308.6

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 2026862,79811.88%+9%113,9637.6
Oct 15, 2026792,55310.91%+13%213,8513.7
Sep 30, 2026702,1989.67%+111%666,0761.1
Sep 15, 2026332,1054.57%+4%136,2592.4
Aug 31, 2026318,4204.38%-3%180,6711.8
Aug 14, 2026327,4424.51%-6%200,8901.6
Jul 31, 2026349,8760.36%+14%184,6441.9
Jul 15, 2026307,8910.32%+3%138,6602.2
Jun 30, 2026298,0770.31%+8%111,2002.7
Jun 15, 2026274,9830.28%-1%73,7073.7
May 29, 2026277,6940.28%+9%107,1682.6
May 15, 2026255,1570.26%-12%2.03M1.0

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Cue Biopharma company events

Cue Biopharma filed 17 reports on Form 8-K in the last 12 months, 8 of them about an important change (leadership). The latest was on Sep 21, 2026.

  1. Sep 21, 2026AnnouncementOf this Current Report on Form 8-K. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The Company is hosting a conference call and live webcast to discuss the clinical data on September 21, 2026 at 8:00 a.m. Filing
  2. Aug 14, 2026ResultsReleased financial results. Filing
  3. Aug 3, 2026LeadershipCue Biopharma, Inc. announced that the Company’s Board of Directors appointed James Ahlers as the Company’s Chief Financial Officer, effective as of July 30, 2026. Filing
  4. Jul 10, 2026LeadershipTo implement the Company’s 2026 Stock Incentive Plan and long-term incentive framework, both approved at the most recent shareholder meeting, the Company’s board of directors granted on July 9, 2026 an aggregate of 1,064,492 restricted stock units to its employees and executive officers as one-time… Filing
  5. Jun 3, 2026LeadershipAt the Special Meeting of Stockholders of Cue Biopharma, Inc. held on June 1, 2026, the Company’s stockholders approved the Cue Biopharma, Inc. 2026 Stock Incentive Plan, which had previously been adopted by the Board, subject to stockholder approval. Filing
  6. Jun 2, 2026LeadershipCue Biopharma, Inc. and each of Jill Broadfoot, Peter Kiener, Frank Morich and Patrick Verheyen mutually agreed that Messrs. Kiener, Morich and Verheyen and Ms. Broadfoot would resign as members of the Board of Directors of the Company and as members of the committees of the Board on which they… Filing
  7. May 1, 2026LeadershipThe Board adopted the Company’s 2026 Inducement Stock Incentive Plan, pursuant to which the Company may grant nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock units, other stock-based awards, and performance awards with respect to an aggregate of… Filing
  8. Apr 22, 2026SharesChanged the rights of its shareholders. Filing
  9. Apr 13, 2026VoteReported shareholder vote results. Filing
  10. Apr 7, 2026AnnouncementCue Biopharma, Inc. received notice from Boehringer Ingelheim that Boehringer Ingelheim had approved selection of its first compound for lead optimization under the Collaboration and License Agreement entered into with Boehringer Ingelheim on April 10, 2025 for the research, development and… Filing
  11. Mar 27, 2026LeadershipThe Board of Directors of Cue Biopharma, Inc. appointed Lucinda Warren, the Chief Financial and Business Officer of the Company, as Interim President and Chief Executive Officer, effective as of March 27, 2026. Filing
  12. Mar 16, 2026ResultsReleased financial results. Filing
  13. Feb 18, 2026AnnouncementCue Biopharma, Inc. has set April 13, 2026 as the date for the Company’s 2026 Annual Meeting of Stockholders. Filing
  14. Feb 12, 2026LeadershipThe Board of Directors of Cue Biopharma, Inc. appointed Lucinda Warren, the Chief Business Officer of the Company, as Chief Financial and Business Officer of the Company, effective February 9, 2026. Filing
  15. Dec 19, 2025AgreementCue Biopharma, Inc. entered into an underwriting agreement with H.C. Wainwright & Co., LLC, as representative of the several underwriters named therein, relating to an underwritten public offering of (i) 12,500,000 shares of the Company’s common stock, $0.001 par value per share, and accompanying… Filing
  16. Nov 24, 2025AnnouncementShared information with investors. Filing
  17. Nov 20, 2025LeadershipCue Biopharma, Inc. and Matteo Levisetti, Chief Medical Officer, agreed that Dr. Levisetti’s employment with the Company will terminate effective November 28, 2025. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Cue Biopharma financials

Famous investors that hold CUE

3 of the 50 well-known investors we track reported holding CUE in their latest 13F filing. The largest position is Israel Englander's, worth $1.1M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Israel Englander · Millennium ManagementQ3 202644,356$1.1M0.0%New
Ken Griffin · Citadel AdvisorsQ3 202619,808$512K0.0%-23%
Jim Simons · Renaissance TechnologiesQ3 202610,289$266K0.0%-30%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 10 filings named CUE in the last 120 days.

FiledHolderFormStake
Nov 16, 2026BALYASNY ASSET MANAGEMENT L.P.13G5.9%
Nov 16, 2026Cormorant Asset Management, LP13G10.0%
Nov 16, 2026BALYASNY ASSET MANAGEMENT L.P.13G5.9%
Nov 16, 2026Cormorant Asset Management, LP13G10.0%
Nov 16, 2026DRIEHAUS CAPITAL MANAGEMENT LLC13G/A4.0%
Nov 16, 2026DRIEHAUS CAPITAL MANAGEMENT LLC13G/A4.0%
Nov 10, 2026Bleichroeder LP13G/A8.8%
Nov 10, 2026Bleichroeder LP13G/A8.8%
Oct 8, 2026Mark E. Strome13G/A8.5%
Oct 8, 2026Mark E. Strome13G/A8.5%

Questions about Cue Biopharma, Inc. (CUE) stock

Who owns the most CUE stock?

The largest reported owner of Cue Biopharma, Inc. (CUE) is Bleichroeder LP, with 0.4% of the company. In total, 48 funds and institutions reported holding CUE at the end of Q2 2026, together about 2% of the shares. See the largest owners.

Are CUE insiders buying or selling?

In the last 12 months, CUE insiders reported no open-market purchases and 15 sales worth $2.4M. The latest trade was on Oct 12, 2026. See every trade.

What is the short interest in CUE?

As of Oct 30, 2026, 862,798 CUE shares were sold short, 11.9% of the shares outstanding, up 8.9% from the report before. At the average daily volume of 113,963 shares, buying them all back would take about 7.6 trading days (days to cover). See the history.

Which famous investors hold CUE?

3 of the 50 well-known investors we track reported CUE in their latest 13F filing, including Israel Englander, Ken Griffin, Jim Simons. The largest position is worth $1.1M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.